| Code | CSB-RA020978MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Inclacumab, targeting SELP (P-selectin, also known as CD62P). SELP is a cell adhesion molecule expressed on activated endothelial cells and platelets that mediates the initial tethering and rolling of leukocytes on the vascular endothelium during inflammation. Upon cellular activation, P-selectin is rapidly translocated from intracellular granules to the cell surface, where it binds to PSGL-1 on leukocytes, facilitating their recruitment to sites of inflammation and thrombosis. Dysregulated SELP expression is implicated in various pathological conditions, including cardiovascular disease, thrombotic disorders, inflammatory diseases, and cancer metastasis.
Inclacumab is a humanized IgG4 monoclonal antibody that was investigated in clinical trials for its potential to reduce myocardial damage following acute myocardial infarction by blocking P-selectin-mediated inflammatory responses. This biosimilar antibody serves as a valuable research tool for investigating P-selectin biology, studying leukocyte-endothelial interactions, exploring mechanisms of thromboinflammation, and evaluating therapeutic strategies targeting adhesion molecule pathways in preclinical models.
There are currently no reviews for this product.